2016 American Transplant Congress
Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients.
Purpose: aHUS often progresses to ESRD and requires transplant (tx). Eculiumab (ECU), a terminal complement inhibitor, inhibits TMA irrespective of tx status. We evaluated outcomes…2016 American Transplant Congress
Early Post Renal Transplant aHUS in Patients with Heterozygous CFHR3-CFHR1 Deletion.
Renal Division, Washington University, Saint Louis, MO.
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease with a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Subjects homozygous for…2016 American Transplant Congress
Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience.
Kidney transplant recipients (KTRs) with Hepatitis C virus infection (HCV+ve) have higher proteinuria and inferior patient and graft survival compared to HCV negative KTRs. Due…2016 American Transplant Congress
Predicting the Timing of Graft Failure in De Novo DSA Positive Patients.
The risk of graft failure after de novo DSA (dnDSA) is not always immediate. To make more informed therapeutic decisions in dnDSA+ patients, we need…2016 American Transplant Congress
Non-Invasive – Minimalistic Approach Using Cell-Free MicroRNAs in Paired Plasma and Urine Samples for Early Diagnosis of Chronic Renal Allograft Dysfunction.
1Surgery, UVA, Charlottesville, VA; 2VCU, Richmond; 3NWU, Chicago.
Background: Reducing use of tissue biopsy by efficiently using non-invasive samples for continuous monitoring and evaluation of graft function would be ideal. Reports indicate continuous…2016 American Transplant Congress
IgG Dilutions, Subclasses, C1q, and IgM: Determining Relevant Testing for De Novo DSA and Outcome Prediction.
Numerous publications have shown secondary antibody testing of IgG (subclasses, C1q, etc) in de novo DSA (dnDSA) positive patients may have clinical relevance. Herein, we…2016 American Transplant Congress
Impact of Delayed Graft Function Varies by Demographic and Clinical Characteristics in Deceased Donor Kidney Transplantation.
Single-center studies have suggested potential differences in the impact of DGF by recipients' biological susceptibility, quality of allograft, and immune compatibility. The goal of this…2016 American Transplant Congress
Lower Renal Graft Function and Accelerated Fibrosis in HIV-Infected Transplant Recipients with Previous HIVAN Compared to Non HIVAN HIV-Positive Transplant Recipients.
Several studies reported reduced renal allograft survival rates among HIV-infected transplant recipients. Few data focus on histological lesions and their progression in renal grafts from…2016 American Transplant Congress
Dynamics of Delayed Graft Function-Associated Risk in Deceased Donor Kidney Transplantation.
The long-term implications of delayed graft function (DGF) remain controversial. Moreover, non-proportional hazards of DGF have been reported in previous studies, which suggested that its…2016 American Transplant Congress
Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.
Medicine, University Hospitals Case Medical Center, Cleveland, OH.
Background: Late acute rejection (AR) is associated with inferior outcomes relative to early AR after kidney transplantation. We sought to examine the differences in risk…
American Transplant Congress abstracts